Navigation Links
Biomarkers predict risk for invasive breast cancer years before the tumor develops
Date:11/12/2007

A team of scientists from the University of California San Francisco has identified distinct molecular markers that predict whether or not a woman is likely to develop subsequent invasive cancer after initial diagnosis with a noninvasive form of early breast cancer. The research, published by Cell Press in the November issue of Cancer Cell, provides critical information that can be used to determine whether a woman should receive more or less aggressive therapy.

Approximately 12-15% of women diagnosed with ductal carcinoma in situ (DCIS), a tumor limited to milk ducts, develop a subsequent invasive cancer event within the first decade after surgical lumpectomy. However, due to the absence of reliable predictors to identify those women that will develop future tumors formation, all women diagnosed with DCIS tend to be offered similar treatment options. Identification of biomarkers that predict future tumor development would allow us to stratify a womens individual risk for subsequent invasive tumors and avoid over- and under- treatment, says lead author Dr. Thea D. Tlsty and clinician, Dr. Karla Kerlokowske, both from the Comprehensive Cancer Center at the University of California San Francisco.

Dr. Tlsty, Gauthier and Berman hypothesized that cells capable of activating pathways linked to stress-induced cell death would not form subsequent tumors while cells that bypass stress signals would be more likely to eventually progress to tumor formation. The researchers evaluated molecular characteristics and their association with outcome in a group of women diagnosed with DCIS and found that expression of biomarkers indicative of a short-circuited response to cellular stress predicts DCIS with a worse outcome and is a defining characteristic of an aggressive phenotype called basal-like tumors. Conversely, a disease-free prognosis is associated with an intact response to cellular stress.

Mechanistic studies indicated that deregulation of t
'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
2. Study makes progress in zoning in on biomarkers for better colon cancer treatment
3. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
4. UCLA researchers identify markers that may predict diabetes in still-healthy people
5. Use of certain lipid measures not more effective in predicting coronary heart disease
6. First biomarker discovered that predicts prostate cancer outcome
7. Brain Lesions Predict MS Progression
8. ZIP codes and property values predict obesity rates
9. Work Time Predicts Sleep Time
10. Thomson Scientific Predicts Nobel Laureates
11. Segal Survey Predicts Declines in Trends for Fifth Consecutive Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... drug which is typically used for treating colorectal cancer. ... treating gastric cancer and pancreatic cancer. TS-1 is composed ... first approved in 1999 in Japan for the treatment ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... during and after being treated with post-surgical chemotherapy did not ... from it, according to researchers at Dana-Farber Cancer Institute. ... characterized as cancer in the large bowel area with ... the researchers found that while multivitamin use had no beneficial ...
... of smoking cessation treatments are currently available for the ... smoking each year, but success rates vary widely. Despite ... smoking cessation treatment are needed to help smokers pick ... A major new personalized medicine clinical trial, led by ...
... an intense network of collaborative research. Building on a tool ... recent issue of Brain , Dr. Yaniv Assaf of ... international team of scientists to understand how different parts of ... into a "brain atlas." Brain researchers already know that ...
... disease deaths and hospital admissions, particularly among people from ... Journal of Epidemiology and Community Health . Current ... has improved the overall quality of primary care in ... evidence to suggest that better quality primary care actually ...
... on conserving the use of antibacterial drugs, or face ... antibiotic-resistant infections, according to an analysis out today. ... being depleted by resistance, which occurs when infection-causing microbes ... to widely-used treatments. Most proposals to solve this problem ...
... of California, San Diego School of Medicine have shown ... examining dynamic geometric patterns than they do looking at ... either typical or developmentally delayed toddlers. The results ... patterns early in life may be a signature behavior ...
Cached Medicine News:Health News:Multivitamin use doesn't impact colon cancer outcomes 2Health News:Penn receives $12 million NIH grant to research personalized approach to smoking cessation 2Health News:Mapping a brain atlas 2Health News:Primary care financial incentives cut heart disease deaths and admissions 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 3Health News:Visual pattern preference may be indicator of autism in toddlers 2Health News:Visual pattern preference may be indicator of autism in toddlers 3
(Date:12/24/2014)... /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine ... released unaudited preliminary financial results for the first ... Year 2015 Ended September 30, 2014 Financial Highlights: ... $14.7 million in 1Q14 with gross margins improved ...
(Date:12/24/2014)...  Conkwest, Inc., the Natural Killer Cell Company ... (NK) cell-line platform, Neukoplast® (NK-92™) as an immuno-oncology ... NantWorks founder, physician scientist and biotechnology entrepreneur, has ... $48 million of the Company,s Class A Common ... be named Co-Chairman of the Conkwest Board of ...
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, ... of over-the-counter (OTC) medicinal and healthcare products, announced it ... MigraPure® H, a hemp-based, advanced headache relief product, for ... in Colorado , Washington ... With the MigraPure H Advanced headache relief ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... June 28 Ortho-McNeil-Janssen Pharmaceuticals, Inc. ... agreement with the David H. Koch Institute for ... of Technology .  Called TRANSCEND, the collaboration agreement ... the areas of cancer diagnostics, cancer biology pre-malignancies, ...
... 28 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ... Index on June 25, 2010 , when Russell Investments reconstituted its ... , ... on a national exchange, is consistent with our goal of increasing awareness ...
Cached Medicine Technology:Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT 2ADVENTRX Added to Russell Microcap Index 2
Non-Illuminated Trial Lens Set is an attractive set of trial lenses worked to a high standard of accuracy....
Trial Lens Sets....
... disc test (P/N LD15C) include a durable ... instructions. P/N LD15C also includes a Plexiglas ... covers for the test subjects fingers ( ... color discs). Beware that these finger cots ...
Opti-Free Express multi-purpose disinfecting solution lasting comfort No Rub formula provides triple action protection for your contact lenses....
Medicine Products: